Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Developments

Pliant assembles expert panel to review bexotegrast trial data in IPF

Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review...

February 13, 2025

Developments

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed...

February 13, 2025

Developments

Top-tier journal describes unique properties of Aclaris’ ATI-2138

Aclaris Therapeutics (NASDAQ:ACRS) has announced that a publication in The Journal of Pharmacology and Experimental Therapeutics describes the unique properties its investigational drug, ATI-2138, which is in...

February 12, 2025

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Developments

FOX 26 interview with Baylor’s Alastair Thompson discusses achieving clear margins in breast cancer surgery with Perimeter’s investigational B-Series OCT with ImgAssist AI 2.0

A FOX26 news interview featuring Dr. Alastair Thompson, a surgical oncologist at Baylor College of Medicine and the lead principal investigator of Perimeter Medical Imaging AI’s (TSX: PINK; OTC: PYNKF) pivotal trial on...

February 11, 2025

Executive Moves

Titan launches equity research division; names Boris Peaker senior healthcare analyst

Titan Partners Group, a division of American Capital Partners, has announced the launch of its equity research division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research...

February 11, 2025

Developments

Firefly accepted into NVIDIA Connect program

Firefly Neuroscience (NASDAQ:AIFF) has announced its acceptance into the NVIDIA Connect program, granting access to advanced software development resources, frameworks, software development kits, and a global ecosystem...

February 11, 2025

Developments

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a...

February 11, 2025

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Developments

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a...

February 10, 2025

Subscribe